Johnson & Johnson vs Roche

8-K Financial Filing Analysis for Johnson & Johnson

Johnson & Johnson filed a Form 8-K under Item 2.02 (Results of Operations and Financial Condition) on July 15, 2026, announcing its financial results for the fiscal second quarter ended June 28, 2026. The filing furnishes the official quarterly press release alongside unaudited comparative supplementary sales data and condensed consolidated statements of earnings for both the second quarter and the first six months of the fiscal year.

• Johnson & Johnson released its sales and earnings report for the second quarter ended June 28, 2026, via Item 2.02.
• The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings).
• The report was formally signed on July 15, 2026, by Controller and Principal Accounting Officer Robert J. Decker, Jr.

Lisa Maxwell: Organizations Struggle to Align, Not to Answer

Lisa Maxwell, vice president of B2B marketing at Mastercard and juror on The Drum B2B Awards Industry jury, argues that organizational failure in marketing stems from misalignment between teams solving different problems rather than a lack of answers. She advocates starting marketing work by identifying what audiences need to understand to act, building shared understanding across stakeholders, and investing in stakeholder insight before platform or channel choices. Maxwell says AI can generate information quickly but cannot observe or interpret human behaviour, so the human advantage lies in judgment and interpretation. She also emphasizes that B2B marketing must account for human decision‑making within organisations and highlights curiosity and discernment as key leadership traits for the next generation of marketers.

• Lisa Maxwell is vice president of B2B marketing at Mastercard.
• Maxwell serves as a juror on the Industry jury for The Drum B2B Awards.
• Maxwell previously worked at Johnson & Johnson and GlaxoSmithKline Consumer Healthcare before moving into financial services.

Eva Messerschmidt Leads RTL Communications; Lisa Steiner Deputy

Following RTL Deutschland’s takeover of Sky Deutschland, Eva Messerschmidt will remain head of RTL Deutschland’s communications as Executive Vice President. Lisa Steiner, who led Sky’s communications since June 2024, will join as Messerschmidt’s deputy. Messerschmidt will oversee overall communications and digital development of the communications area and the staging of content across platforms; Steiner will focus on transformation communication and internal integration and leadership communication. The appointment continues post-merger integration of the two companies’ communications teams. The piece includes background on both executives’ prior roles and a statement from RTL Deutschland CEO Stephan Schmitter highlighting the importance of strategic communication during the merger.

• Eva Messerschmidt will remain head of RTL Deutschland communications as Executive Vice President after the Sky Deutschland takeover.
• Lisa Steiner, who led Sky’s communications since June 2024, will serve as Messerschmidt’s deputy.
• Messerschmidt has been responsible for RTL Deutschland communications since March 2023.

Roche and Ypsomed Stay Top in Swiss Reputation Ranking

Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method to evaluate media reputation for 40 pharma and medtech companies. The study measured presence (coverage and reach) and tonality (positive/negative reporting) and calculated a Reputation Score (0–100) for each company across six reputation dimensions. In Pharma & Biopharma, Roche ranks first (ahead of MSD, Novartis, Sandoz and AstraZeneca). In MedTech & Diagnostics, Ypsomed remains first (ahead of Medacta, Straumann Group, Alcon and Sonova). The study notes products/services, innovation and economic performance tended to improve media reputation, while workplace issues (layoffs, relocations) and ESG/legal problems harmed reputation. The article was published on 2026-08-13.

• Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method.
• The study measured presence and tonality for 40 pharma and medtech companies and computed a Reputation Score between 0 and 100 across six reputation dimensions.
• In the Pharma & Biopharma category, Roche ranked first, followed by MSD, Novartis, Sandoz and AstraZeneca.

Roche Pharma Day 2026 announced

Roche Pharma Day 2026 will be held on Monday, 28th September 2026, 09:00am BST. More details available via the investor update.

Investor Presentation Released: Roche

AI parsed presentation narrative: Roche is successfully transitioning to a post-pandemic growth phase, with base business growth of 7% and core operating profit expanding faster than sales. The strategy focuses on maximizing high-growth franchises like Vabysmo and Ocrevus while aggressively expanding into the obesity market and AI-driven diagnostics. Strategic pillars: Maximizing value of existing growth drivers, Leading in Obesity and Metabolic disease.